The stock market indices started off with a firm opening, then backed and filled in the morning, but held support, and rallied strongly and sharply, taking the Nasdaq 100 from 4152 to 4180. The S&P 500 jumped from 2030 to 2039. Then they backed off, backed and filled the rest of the day, closing with a little bounce.

Net on the day, the Dow was up 39.81 at 16,613.74, a new all-time high close. The S&P 500 was up 6.34 at 2038.26, also a new all-time high close. The Nasdaq 100 was up 15.44 at 4175.95, not far from key resistance now overhead around 4180, which is the 14-year high.

Advance-declines were 17 to 13 positive on the New York Stock Exchange, and 16 1/2 to 10 positive on Nasdaq. Up/down volume was flat, but slightly positive by 800,000 shares, or 16 to 15 on New York, with total volume of 3.2 billion shares. Nasdaq traded 1.8 billion shares, and had a 4 to 3 positive volume ratio.

TheTechTrader.com board was mixed but mostly higher. Priceline.com Incorporated (PCLN) led the way, up 25.41 to 1120.02. Google Inc. (GOOG) was up 6.48 to 547.49, Apple Inc. (AAPL) down slightly to 108.83, Amazon.com Inc. (AMZN) up 5.25 to 305.11, and Netflix, Inc. (NFLX) up 3.11 to 387.27.

Pharmacyclics Inc. (PCYC) edged ahead by 49 cents to 133.98, Tesla Motors, Inc. (TSLA) gained 1.73 to 241.93, and Vipshop Holdings Limited (VIPS) popped 1.17 to 24.51.

ALIBABA GROUP HOLDING LTD (BABA) was up 4.59 to 119.15, closing near the post-IPO, all-time highs. Agios Pharmaceuticals, Inc. (AGIO) was up 9.72 to 81.78, swing-trade Achillion Pharmaceuticals, Inc. (ACHN) up 2.74 to 12.85 on 28 million shares, Ambarella, Inc. (AMBA) 2.07 to 49.21,Cyber-Ark Software Ltd. (CYBR) 2.17 to 34.88, and Celldex Therapeutics, Inc. (CLDX), another one of our swing trades, 1.39 to 14.81.

Canadian Solar Inc. (CSIQ), in a firm solar sector, gained 1.45 to 31.72. First Solar, Inc. (FSLR) ran 1.67 to 51.96, FireEye, Inc. (FEYE) popped 1.77 to 32.39, swing-trade NewLink Genetics Corporation (NLNK) advanced 2.25 to 34.40, and swing-trade VASCO Data Security International (VDSI) jumped another 1.64 to 28.27.

On the downside, gold had a difficult session, and gave back a big chunk. Royal Gold, Inc. (RGLD) dropped 3.47 to 61.95, and GoPro, Inc. (GPRO) gave back 3.31 to 75.75.

Checking the TheTechTrader.com percent-gain leaderboard, Planar Systems Inc. (PLNR), following through from Friday's gain, had a big day, up 1.28 to 7.68, or 20%, on 5.2 million shares.

Orexigen Therapeutics, Inc. (OREX), on positive drug news, led the way today, up 1.28 to 5.13, or 33%, on 15.4 million shares.

Dean Foods Company (DF) gained 1.98 to 16.40, or 14%, on 10.6 million shares. Vitae Pharmaceuticals, Inc. (VTAE) climbed 1.95 to 16.39, or 13 1/2%. TG Therapeutics, Inc. (TGTX) bounced 1.28 to 12.55, or 11%.

The Direxion Daily Jr Gld Mnrs Bear 3X ETF (JDST) ran 4.05 to 29.05, or 16%, on 4.1 million shares. The Direxion Daily Gold Miners Bear 3X Shrs (DUST) ran 5.97 to 39.88, or 11%, on 4.8 million shares.

Among other gainers, Gogo Inc. (GOGO) popped up 1.76 to 18.40, and Forward Pharmaceutical (FWP) closed up 2.16 to 23.21.

Stepping back and reviewing the hourly chart patterns, after a brief dip early on, the indices ran sharply higher to test key-resistance on the Nasdaq 100 at 4180, and set new all-time highs on the S&P 500 at 2038.70. They backed and filled the rest of the day. It was a positive session to start the week with fairly good technicals.

Let's see what happens tomorrow.

Good Trading!

In using any portion of The Technical Trader, you agree to the Terms and Conditions governing the use of the service as described in this disclaimer. Our disclaimers, policies and terms are subject to change without notice. The Technical Trader (www.thetechtrader.com) is published by Century-Pacific Investments and AdviceTrade, Inc., both of which are publishers. The Web site is maintained by Codexia, LLC. None of these firms, nor Mr. Boxer, is registered as a broker-dealer or investment adviser either with the U.S. Securities and Exchange Commission or with any state securities authority. Each trade mentioned in the diary and other sections of The Technical Trader is hypothetical and is not an actual trade. Mr. Boxer and employees of Century-Pacific, AdviceTrade and Codexia are not allowed to have personal positions in stocks mentioned in the diary and other sections of The Technical Trader. This policy, first announced to subscribers on June 2, 2004, gave Mr. Boxer a deadline that was extended to July 30, 2004 for liquidating any existing personal holdings in stocks mentioned on the site. Our holdings page, in which Mr. Boxer listed his personal positions in stocks mentioned on the site, was removed at that time. The publishers are not permitted to have any financial relationship with companies mentioned on the site. Mr. Boxer may recommend trades of stocks mentioned in the Diary as a consultant to hedge funds, but has agreed not to make such recommendations until after the stock has been posted on The Technical Trader Web site. Mr. Boxer's commentaries, trading ideas and model trades represent his own opinions and should not be relied upon for purposes of effecting securities transactions or other investing strategies, nor should they be construed as an offer or solicitation of an offer to sell or buy any security. You should not interpret Mr. Boxer's opinions as constituting investment advice. Neither we nor Mr. Boxer claim to have any non-public information regarding the companies mentioned in this site. The trade prices that appear on this Web site are based on the average of the real-time bid and real-time ask prices provided by Money.net, except when entered manually by Mr. Boxer should Money.net's feed be temporarily down. There may be a delay between the price as it appears in the diary and the current price that you see from your terminal due to delays in Internet connectivity, quote delays, refresh intervals in the case of the Web-based diary page, data entry errors, and market conditions, and also due to times when Mr. Boxer is not available to make the trade at the moment a previously stated target has been met. Entries may at times be in error due to system or data-entry errors. Hypothetical performance results do not include trading commissions and other execution costs that would be incurred if the trades referenced in the diary or elsewhere on the site were actual trades. Past performance is no guarantee of future results.

Recommended Content


Recommended Content

Editors’ Picks

AUD/USD hovers around 0.6500 amid light trading, ahead of US GDP

AUD/USD hovers around 0.6500 amid light trading, ahead of US GDP

AUD/USD is trading close to 0.6500 in Asian trading on Thursday, lacking a clear directional impetus amid an Anzac Day holiday in Australia. Meanwhile, traders stay cautious due ti risk-aversion and ahead of the key US Q1 GDP release. 

AUD/USD News

USD/JPY finds its highest bids since 1990, near 155.50

USD/JPY finds its highest bids since 1990, near 155.50

USD/JPY keeps breaking into its highest chart territory since June of 1990 early Thursday, testing 155.50 for the first time in 34 years as the Japanese Yen remains vulnerable, despite looming Japanese intervention risks. Focus shifts to Thursday's US GDP report and the BoJ decision on Friday. 

USD/JPY News

Gold price lacks firm intraday direction, holds steady above $2,300 ahead of US data

Gold price lacks firm intraday direction, holds steady above $2,300 ahead of US data

Gold price remains confined in a narrow band for the second straight day on Thursday. Reduced Fed rate cut bets and a positive risk tone cap the upside for the commodity. Traders now await key US macro data before positioning for the near-term trajectory.

Gold News

Injective price weakness persists despite over 5.9 million INJ tokens burned

Injective price weakness persists despite over 5.9 million INJ tokens burned

Injective price is trading with a bearish bias, stuck in the lower section of the market range. The bearish outlook abounds despite the network's deflationary efforts to pump the price. Coupled with broader market gloom, INJ token’s doomed days may not be over yet.

Read more

Meta Platforms Earnings: META sinks 10% on lower Q2 revenue guidance Premium

Meta Platforms Earnings: META sinks 10% on lower Q2 revenue guidance

This must be "opposites" week. While Doppelganger Tesla rode horrible misses on Tuesday to a double-digit rally, Meta Platforms produced impressive beats above Wall Street consensus after the close on Wednesday, only to watch the share price collapse by nearly 10%.

Read more

Majors

Cryptocurrencies

Signatures